CAR-T therapy just did what decades of drugs couldn't — it wiped out three simultaneous autoimmune diseases in one patient and sent her home healthy. This isn't tinkering around the edges, it's a full immune system reboot that let a mother finally spend real time with her kids. The science is clear: targeted CAR-T cell treatment offers the possibility of permanent recovery, not just symptom management.
One dramatic recovery doesn't make CAR-T a proven cure. The evidence base is still a tiny, uncontrolled case series with no long-term data beyond a year or two. Costs run up to $530,000 per patient, manufacturing is slow, and risks like B-cell aplasia and cytokine release syndrome are real. Calling this a breakthrough before large randomized trials confirm it sets dangerous expectations.
© 2026 Improve the News Foundation.
All rights reserved.
Version 6.18.0